

Table of Contents

Overview	10	Emergency Hormonal Contraception	39
Sexual Health & Fertility intro	11	Broad geographic availability, but challenges remain	40
Sexual Health & Fertility in the news	12	USA dominated by single marketer	42
Birth and fertility rates declining, particularly in developed markets	15	Plan B One-Step a key player in the US market	44
Pandemic's effects on sexual activity mixed	17	China's No.1 brand supported by extensive health education	45
Female empowerment a significant growth driver	18	India faces challenge from widened availability of daily OC	47
Contraception	19	Italy slow to liberalise EHC market, but saw sales surge in 2021	48
2019 UN study provides insight into birth control use worldwide	20	Germany faces growing generic competition for brands	49
Daily OC	24	Plan B and ellaOne key players in other top markets	51
UN reports significant increase in daily OC use 1994-2019	25	Steady growth, with some potential for switches	53
Overview of key ingredients	26	Condoms	56
Potential for category to expand outside Asia	27	Popular form of contraception seeing diversification of key brands	57
China's dominant brand Yasmin benefits from challenging A+P	28	In USA lower-tier options outperformed established leading brands	59
South Korea's market opening up via NPD	30	Marketing in Brazil promotes safe and enjoyable sex	60
India sees daily OC reform	33	Trojan retains commanding lead in USA thanks to focus on pleasure	61
Round-up of other markets	34		
Switches in UK may open up European market	35		
Category has potential for expansion in the long term	37		

Table of Contents

Condoms (cont.)		Pregnancy & Pre-pregnancy Vitamins	91
Durex has built a foundation of socially-conscious marketing	62	Conception through to pregnancy	92
Female condoms a growing segment	66	Key vitamins & their benefits	93
Other Contraceptives	69	Importance of HCPs / NPD focus	95
Spermicides available in pharmacies in certain markets	70	Global trends	96
Alternative methods generally HCP-focused	71	USA bolstered by NPD and premium-price launches	98
Fertility & Pregnancy	73	China finds growth despite falling birth rates	103
Pregnancy & Ovulation Tests	74	Italy sees top tier perform well	106
Established category with generally high demand	75	Germany dynamic thanks to increasing birth rate	107
Consumerised US market maintained growth	77	Mexico sees strong showing from leading brands	109
Clearblue an international success via many firsts	78	Brazil's strong growth driven by two dominant brands	110
First Response focuses on speed of results	80	Global leading brands	112
US innovations driven by female-led companies	82	Elevit global leading pregnancy vitamin range	113
Modern Fertility focuses on building a community	83	Femibion a key brand in Europe	114
Clearblue an innovative presence in UK	85	Outlook	115
Generic competition significant in Germany	87	Male fertility VMS offers burgeoning niche	116
First Response a bright spot in Australian market	88	Other Fertility CHC	118
Sales in Brazil dynamic despite lack of A+P	89	Fertility lubricants: Small segment sees growing interest	119
Generics a significant presence in France	90		

Table of Contents

FemTech	120	Erectile Dysfunction (cont.)	
One size does not fit all in women’s health	121	New Zealand sees “first in world” OTC reclassification for ED	146
Clue an early entrant in FemTech segment	123	Topical options include Futura’s MED3000 ED gel	147
Natural Cycles offers a first-in-class birth control app	124	Switch prospects	149
Elvie addresses breastfeeding and pelvic floor exercise	126	Forecasts predict a category that could skyrocket with switches	152
Peptonic Medical building portfolio of FemTech brands	127	“Male vitality” supplements offer VMS alternative	153
Vira Health developing innovative menopause app	130	USA offers array of supplements for sexual performance	154
Prima-Temp partners with CHC brand Enfamil	132	Russia’s sexual health supplements continue to decline	156
Vivant extends FemTech apps into India and other Asian markets	134	Limited selection in other markets	157
Conclusions	135	Latest launch activity offers little innovation	158
Sexual Health Problems	136	Premature Ejaculation	159
Broad range of issues partially addressed by OTC	137	Prevalence and treatment options	160
Erectile Dysfunction	138	Fortacin’s EU-wide switch brings new OTC treatment	162
Most common sexual dysfunction in men	139	Female Sexual Dysfunction	164
Sildenafil-based treatments OTC in a handful of markets	140	Complex condition slowly gaining acceptance	165
Poland boasts largest OTC market for ED treatments in 2021	141	Available treatment options for FSD	166
UK market created by switch of Viagra	143		
Viagra Connect makes OTC debut in UK	144		

Table of Contents

Sexually Transmitted Diseases	169	Intimate Care (cont.)	
Access to STD testing via health services commonplace	170	Russian FIC market expanded by NPD	197
Treatment likely to remain Rx but self testing a growing segment	171	Brazil sees high levels of NPD boost FIC growth	198
Growing number of home HIV tests in Europe	172	Poland FIC market seeing increasing crossover with sexual health	200
Growing number of markets liberalising access to HIV tests	173	Global FIC growth expected to accelerate as taboos break down	201
myLAB BOX a key player in US STD testing	174	VYI brands increasingly branching into FIC	202
OraQuick groundbreaking oral HIV test / Better2Know premium test kits	175	Growing trend for male intimate care	206
SH:24 in UK bridges gap between HCPs and self-testing	176		
FemiClear offers relief of genital herpes symptoms	177	Menstruation	209
Self-tests for chlamydia a small segment in German pharmacy market	178	Period Pain	210
Intimate Care	179	Niche for menstrual pain growing worldwide	211
Feminine intimate care has good global spread	180	In USA Midol faces growing competition from big pain relief brands	212
China's FIC market dominated by domestic brands	183	In China MNCs fight for share with domestic TCM brands	216
USA's FIC growth boosted by NPD and high levels of A+P	185	Japan has well-developed niche for menstrual pain	217
Honey Pot premium FIC range causing a buzz	189	Brazil menstrual pain segment developing rapidly	219
Large French FIC market struggled in recent years	190	Room for development in many key European markets	222
Italy's FIC market experiencing ups and downs	193	Breaking stigma key to building the market in India	227
Vagisan holds lead of German FIC despite increasing competition	195		

Table of Contents

PMS	228	Menopause	236
Premenstrual syndrome and premenstrual dysphoric disorder	229	Herbal menopause supplements sales static globally	237
Causes & symptoms of PMS	230	China's herbal menopause supplements growing well	239
Common ingredients to alleviate PMS	231	New launches could expand struggling US market	241
Launch activity among branded PMS remedies	232	Japan's sales hit hard by Covid-19 pandemic	247
Flo claims to be first PMS remedy in gummy format	233	European markets in need of a boost	249
Consumer preference for drug-free remedies boosts sales of AZO Hormonal	234	Mexico sees category slowly becoming more consumer-oriented	257
Oxaloacetate, ingredient approved for PMS symptoms	235	Herbal menopause supplements in need of innovation	258